Acquisition of WEECO Pharma: SYNBIOTIC significantly expands its position in
the medical cannabis market

EQS-News: SYNBIOTIC SE / Key word(s): Takeover
Acquisition of WEECO Pharma: SYNBIOTIC significantly expands its position in
the medical cannabis market

08.05.2024 / 14:27 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

The German industrial hemp and cannabis group SYNBIOTIC SE acquires WEECO
Pharma GmbH from Hildesheim/Germany. The merger makes SYNBIOTIC one of the
most important players on the German and European market for medicinal
cannabis.

'With WEECO Pharma, our group of companies now has a full range of
high-quality cannabis flowers. Together with our other ventures MH medical
hemp and SYNBIOTIC Distribution, we are in a position to offer the full
MedCan range of flowers as well as extracts and dronabinol - especially in
the segment of alternative administration forms,' explains Daniel Kruse, CEO
SYNBIOTIC. 'This will significantly strengthen our market position in the
medical cannabis market.'

'In SYNBIOTIC, the WEECO Pharma team has found a partner that will
consistently continue, accelerate and support its successful growth
trajectory. In this constellation, WEECO Pharma will continue on its chosen
course as a flagship in the medical cannabis sector,' says Malte Johannes,
Managing Director of WEECO Holding. 'I'm not a fan of empty phrases, but
'the whole is greater than the sum of its parts' hits the spot in this
case.'

As a German importer and wholesaler, WEECO Pharma brings together an
international network of medical cannabis producers, including some of the
world's leading EU GMP manufacturers. The company specialises in national
and international trade in medicinal cannabis, including genetics developed
in-house. In addition, WEECO Pharma is increasingly focussing on product
development for extemporaneous formulations in cooperation with selected
pharmacies and doctors.

WEECO also has excellent expertise in the field of new cannabis genetics. In
a facility licensed for scientific purposes in Denmark, WEECO is developing
new cannabis varieties that have their genetic origins in one of the world's
leading cannabis markets in California/USA.

'The acquisition of WEECO Pharma is another key milestone in our successful
buy and build strategy,' says Daniel Kruse, CEO SYNBIOTIC. 'WEECO Pharma's
forecast turnover for 2024 is around five million euros. For SYNBIOTIC, this
would mean that the planned turnover of the entire group could exceed 20
million euros this year. WEECO Pharma should develop into a real asset for
our investors and shareholders.'

Publisher
SYNBIOTIC SE
Daniel Kruse, CEO
Münsterstrasse 336
40470 Düsseldorf
Germany

Media contact
Rüdiger Tillmann
SYNBIOTIC
Public Relations Manager
E-mail ruediger.tillmann@synbiotic.com
Mobile +49 170 9651451
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a listed group of companies in the hemp and cannabis sector and
pursues a buy and build investment strategy focussed on the EU. The group
covers the entire value chain from cultivation to production and retail -
from the field to the shelf. The core businesses of the vertically
integrated company are research and development, production and
commercialisation of hemp, CBD and cannabis products.
SYNBIOTIC has a clear strategy to further expand along the value chains of
its business areas - hemp and CBD, medical cannabis and consumer cannabis.


---------------------------------------------------------------------------

08.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        SYNBIOTIC SE
                   Münsterstr. 336
                   40470 Dusseldorf
                   Germany
   E-mail:         office@synbiotic.com
   Internet:       https://www.synbiotic.com/
   ISIN:           DE000A3E5A59
   WKN:            A3E5A5
   Listed:         Regulated Unofficial Market in Berlin, Dusseldorf,
                   Frankfurt, Munich, Tradegate Exchange
   EQS News ID:    1898893

End of News EQS News Service
---------------------------------------------------------------------------

1898893 08.05.2024 CET/CEST